T2009-007: A Phase I Study Evaluating the Safety, Tolerability and Biological Activity of EZN-3042, a Survivin mRNA Antagonist, Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL).

Trial Profile

T2009-007: A Phase I Study Evaluating the Safety, Tolerability and Biological Activity of EZN-3042, a Survivin mRNA Antagonist, Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL).

Discontinued
Phase of Trial: Phase I

Latest Information Update: 22 May 2015

At a glance

  • Drugs EZN 3042 (Primary) ; Cytarabine; Doxorubicin; Methotrexate; Pegaspargase; Prednisone; Vincristine
  • Indications Acute lymphoblastic leukaemia
  • Focus Adverse reactions; Biomarker; Pharmacogenomic
  • Most Recent Events

    • 07 Mar 2012 Actual patient number (6) added as reported by ClinicalTrials.gov.
    • 07 Mar 2012 Planned end date changed from 1 Aug 2013 to 1 Jun 2012 as reported by ClinicalTrials.gov.
    • 07 Mar 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top